Toll-like receptor ligands: Hygiene, atopy and therapeutic implications

Current Opinion in Allergy and Clinical Immunology

Volumn 4, Issue 6, 2004, Pages 555-561

  Horner, Anthony A ^a,b   Redecke, Vanessa ^a   Razy, Eyal ^a,b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b San Diego   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allergy; Asthma; CpG motif; Hygiene hypothesis; Immunostimulatory sequence oligodeoxynucleotide; Lipopolysaccharide; Peptidoglycan; Toll like receptor

Indexed keywords

LIGAND; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ALLERGIC DISEASE; ALLERGY; ANIMAL MODEL; ASTHMA; ATOPY; CLINICAL PRACTICE; DEVELOPED COUNTRY; DISEASE PREDISPOSITION; HOMEOSTASIS; HOST CELL; HOST RESISTANCE; HYGIENE; HYPERSENSITIVITY; IMMUNE HOMEOSTASIS; IMMUNOREGULATION; IMMUNOSTIMULATION; INCIDENCE; INFLAMMATION; LYMPHOCYTE; MICROBIAL CONTAMINATION; MOLECULAR INTERACTION; PATHOGENESIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW;

ANIMALS; HUMANS; HYGIENE; HYPERSENSITIVITY, IMMEDIATE; LIGANDS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS;

EID: 9644287997     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200412000-00014     Document Type: Review

References (63)

1. Martinez FD, Holt PG. Role of microbial burden in aetiology of allergy and asthma. Lancet 1999; 354 (Suppl. 2):SII12-SII15.
2. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989; 299:1259-1260.
3. Droste JH, Wieringa MH, Weyler JJ, et al. Does the use of antibiotics in early childhood increase the risk of asthma and allergic disease? Clin Exp Allergy 2000; 30:1547-1553.
4. Wills-Karp M, Santeliz J, Karp CL. The germless theory of allergic diseases: revisiting the hygiene hypothesis. Nat Rev Immunol 2001; 1:69-75.
5. Yazdanbakhsh M, Kremsner PG, van Ree R. Allergy, parasites, and the hygiene hypothesis. Science 2002; 296:490-494.
6. von Mutius E. Environmental factors influencing the development and progression of pediatric asthma. J Allergy Clin Immunol 2002; 109:S525-S532.
7. Matricardi PM, Rosmini F, Panetta V, et al. Hay fever and asthma in relation to markers of infection in the United States. J Allergy Clin Immunol 2002; 110:381-387.
8. Aim JS, Swartz J, Lilja G, et al. Atopy in children of families with an anthroposophic lifestyle. Lancet 1999; 353:1485-1488.
9. Shaheen SO, Aaby P, Hall AJ, et al. Measles and atopy in Guinea-Bissau. Lancet 1996; 347:1792-1796.
10. Shirakawa T, Enomoto T, Shimazu S, Hopkin JM. The inverse association between tuberculin responses and atopic disorder. Science 1997; 275:77-79.
11. Matricardi PM, Rosmini F, Riondino S, et al. Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. BMJ 2000; 320:412-417.
12. Matricardi PM, Rosmini F, Ferrigno L, et al. Cross sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus. BMJ 1997; 314:999-1003.
13. Martinez FD. Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr Infect Dis J 2003; 22 (2 Suppl.):S76-S82.
14. Lemanske RF Jr. Viruses and asthma: inception, exacerbation, and possible prevention. J Pediatr 2003; 142 (2 Suppl.):S3-S7; discussion S7-S8.
15. Sigurs N, Bjarnason R, Sigurbergsson F, et al. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 1995; 95:500-505.
16. Boguniewicz M, Leung DY. Pathophysiologic mechanisms in atopic dermatitis. Semin Cutan Med Surg 2001; 4:217-225.
17. Matsui K, Nishikawa A. Lipoteichoic acid from Staphylococcus aureus induces Th2-prone dermatitis in mice sensitized percutaneously with an allergen. Clin Exp Allergy 2002; 32:783-788.
18. Matsui K, Nishikawa A. Lipoteichoic acid from Staphylococcus aureus enhances allergen-specific immunoglobulin E production in mice. Clin Exp Allergy 2003; 33:842-848. This paper and ref. 17 provide direct evidence that cutaneous exposure to a S. aureus-derived TLR2 ligand primes mice for IgE production and experimental eczema.
19. Godfrey RC. Asthma and IgE levels in rural and urban communities of The Gambia. Clin Allergy 1975; 5:201-207.
20. Lynch NR, Hagel I, Perez M, et al. Effect of anthelmintic treatment on the allergic reactivity of children in a tropical slum. J Allergy Clin Immunol 1993; 92:404-411.
21. Bingley PJ, Douek IF, Rogers CA, Gale EA. Influence of maternal age at delivery and birth order on risk of type 1 diabetes in childhood: prospective population based family study. Bart's Oxford Family Study Group. BMJ 2000; 321:420-424.
22. Stene LC, Nafstad P. Relation between occurrence of type 1 diabetes and asthma. Lancet 2001; 357:607-608.
23. Medzhitov R, Janeway C Jr. The Toll receptor family and microbial recognition. Trends Microbiol 2000; 8:452-456.
24. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol 2004; 4:499-511. This review provides an up-to-date and comprehensive summary of our current knowledge of TLRs and their associated signaling pathways.
25. Beutler B. Inferences, questions and possibilities in Toll-like receptor signaling. Nature 2004; 430:257-263.
26. Zhang D, Zhang G, Hayden MS, et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004; 303:1481-1482. These investigators have recently identified TLR11, when previously it was thought that only 10 TLRs were encoded in mammalian genomes. One important implication of these studies is that still other TLRs await discovery.
27. Sudo N, Sawamura S, Tanaka K, et al. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J Immunol 1997; 159:1739-1745.
28. Schnare M, Barton GM, Holt AC, et al. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2:947-950.
29. Kaisho T, Hoshino K, Iwabe T, et al. Endotoxin can induce MyD88-deficient dendritic cells to support T(h)2 cell differentiation. Int Immunol 2002; 14:695-700.
30. Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003; 299:2076-2079.
31. Suzuki N, Suzuki S, Yeh WC. IRAK-4 as the central TIR signaling mediator in innate immunity. Trends Immunol 2002; 23:503-506.
32. Gereda JE, Leung DY, Thatayatikom A, et al. Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisation in infants at high risk of asthma. Lancet 2000; 355:1680-1683.
33. Baldini M, Lohman IC, Halonen M, et al. A polymorphism in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20:976-983.
34. van Strien RT, Engel R, Holst O, et al. Microbial exposure of rural school children, as assessed by levels of N-acetyl-muramic acid in mattress dust, and its association with respiratory health. J Allergy Clin Immunol 2004; 113:860-867. These investigators have recently found that the endotoxin content of dust samples correlates with their content of N-acetyl-muramic acid, a breakdown product of the TLR2 ligand, peptidoglycan.
35. Roy SR, Schlitz AM, Marrotta A, et al. Bacterial DNA in house and farm barn dust. J Allergy Clin Immunol 2003; 112:571-578. In these studies, dust samples from environments with higher endotoxin levels were also found to have increased levels of bacterial DNA, a TLR9 ligand.
36. Purkerson JM, Isakson PC. Independent regulation of DNA recombination and immunoglobulin (Ig) secretion during isotype switching to IgG1 and IgE. J Exp Med 1994; 179:1877-1883.
37. Tulic MK, Wale JL, Holt PG, Sly PD. Modification of the inflammatory response to allergen challenge after exposure to bacterial lipopolysaccharide. Am J Respir Cell Mol Biol 2000; 22:604-612.
38. Eisenbarth SC, Piggott DA, Huleatt JW, et al. Lipopolysaccharide- enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 2002; 196:1645-1651.
39. Van Uden J, Raz E. Immunostimulatory DNA and applications to allergic disease. J Allergy Clin Immunol 1999; 104:902-910.
40. Horner AA, Raz E. Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases. J Allergy Clin Immunol 2002; 110:706-712.
41. Bohle B. CpG motifs as possible adjuvants for the treatment of allergic diseases. Int Arch Allergy Immunol 2002; 129:198-203.
42. Wild JS, Sur S. CpG oligonucleotide modulation of allergic inflammation. Allergy 2001; 56:365-376.
43. Magone MT, Chan CC, Beck L, et al. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur J Immunol 2000; 30:1841-1850.
44. Horner AA, Van Uden JH, Zubeldia JM, et al. DNA-based immunotherapeutics for the treatment of allergic disease. Immunol Rev 2001; 179:102-118.
45. Horner AA, Datta SK, Takabayashi K, et al. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J Immunol 2001; 167:1584-1591.
46. Horner AA, Cinman N, Ronaghy A, Raz E. Mucosal adjuvanticity of immunostimulatory DNA sequences. Springer Semin Immunopathol 2000; 22:133-146.
47. Horner AA, Takabayashi K, Beck L, et al. Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. J Allergy Clin Immunol 2002; 110:413-420.
48. Santeliz JV, Van Nest G, Traquina P, et al. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol 2002; 109:455-462.
49. Takabayashi K, Libet L, Chisholm D, et al. Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in th2-sensrtized mice. J Immunol 2003; 170:3898-3905.
50. Tulic MK, Fiset PO, Christodoulopoulos P, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004; 113:235-241. Results from this clinical trial suggest that ISS oligodeoxynucleotide-conjugated allergens may prove to be safe and effective for the treatment of allergic diseases.
51. Simons FE, Shikishima Y, Van Nest G, et al. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004; 113:1144-1151. This series of investigations demonstrates that injections of ISS oligodeoxynucleotide-conjugated Amb a 1 can redirect allergen-specific immunity in sensitized patients.
52. Pulendran B, Kumar P, Cutler CW, et al. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J Immunol 2001; 167:5067-5076.
53. McCurdy JD, Olynych TJ, Maher LH, Marshall JS. Cutting edge: distinct toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol 2003; 170:1625-1629.
54. Supajatura V, Ushio H, Nakao A, et al. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest 2002; 109:1351-1359.
55. Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 2001; 276:37692-37699.
56. Redecke V, Hacker H, Datta SK, et al. Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol 2004; 172:2739-2743.
57. Chisholm D, Libel L, Hayashi T, Horner AA. Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities. J Allergy Clin Immunol 2004; 113:448-454.
58. Wang L, Smith D, Bot S, et al. Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination. J Clin Invest 2002; 110:1175-1184.
59. Agrawal S, Agrawal A, Doughty B, et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen- activated protein kinase and c-Fos. J Immunol 2003; 171:4984-4989.
60. Didierlaurent A, Ferrero I, Otten LA, et al. Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J Immunol 2004; 172:6922-6930.
61. Vasilakos JP, Smith RM, Gibson SJ, et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol 2000; 204:64-74.
62. Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999; 191:10-19.
63. Brugnolo F, Sampognaro S, Liotta F, et al. The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. J Allergy Clin Immunol 2003; 111:380-388.